25 XP   0   0   10

Acasti Pharma Inc
Buy, Hold or Sell?

Let's analyse Acasti Pharma Inc together

PenkeI guess you are interested in Acasti Pharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Acasti Pharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Acasti Pharma Inc

I send you an email if I find something interesting about Acasti Pharma Inc.

Quick analysis of Acasti Pharma Inc (30 sec.)










What can you expect buying and holding a share of Acasti Pharma Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$4.14
Expected worth in 1 year
$0.70
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-3.44
Return On Investment
-101.1%

For what price can you sell your share?

Current Price per Share
$3.40
Expected price per share
$3.18 - $3.59
How sure are you?
50%

1. Valuation of Acasti Pharma Inc (5 min.)




Live pricePrice per Share (EOD)

$3.40

Intrinsic Value Per Share

$-10.21 - $2.08

Total Value Per Share

$-6.07 - $6.22

2. Growth of Acasti Pharma Inc (5 min.)




Is Acasti Pharma Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$47.6m$75.3m-$26.9m-55.5%

How much money is Acasti Pharma Inc making?

Current yearPrevious yearGrowGrow %
Making money-$7.2m-$3.1m-$4m-55.7%
Net Profit Margin22,724.2%-11,265.1%--

How much money comes from the company's main activities?

3. Financial Health of Acasti Pharma Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#484 / 1031

Most Revenue
#1018 / 1031

Most Profit
#527 / 1031

What can you expect buying and holding a share of Acasti Pharma Inc? (5 min.)

Welcome investor! Acasti Pharma Inc's management wants to use your money to grow the business. In return you get a share of Acasti Pharma Inc.

What can you expect buying and holding a share of Acasti Pharma Inc?

First you should know what it really means to hold a share of Acasti Pharma Inc. And how you can make/lose money.

Speculation

The Price per Share of Acasti Pharma Inc is $3.4. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Acasti Pharma Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Acasti Pharma Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.14. Based on the TTM, the Book Value Change Per Share is $-0.86 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.28 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Acasti Pharma Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.15-4.5%-0.27-7.9%-0.34-9.9%-0.53-15.7%-0.37-10.9%
Usd Book Value Change Per Share-1.09-32.0%-0.86-25.3%-0.28-8.3%0.123.5%0.041.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-1.09-32.0%-0.86-25.3%-0.28-8.3%0.123.5%0.041.3%
Usd Price Per Share2.89-1.66-0.79-1.11-1.10-
Price to Earnings Ratio-4.72--1.97--0.60--0.38--0.52-
Price-to-Total Gains Ratio-2.65-2.11--3.01--1.66--0.74-
Price to Book Ratio0.70-0.36-0.10--0.76-0.04-
Price-to-Total Gains Ratio-2.65-2.11--3.01--1.66--0.74-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.4
Number of shares294
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.860.12
Usd Total Gains Per Share-0.860.12
Gains per Quarter (294 shares)-252.6634.95
Gains per Year (294 shares)-1,010.65139.81
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1011-10210140130
20-2021-20320280270
30-3032-30430419410
40-4043-40540559550
50-5053-50650699690
60-6064-60760839830
70-7075-70870979970
80-8085-8098011181110
90-9096-9109012581250
100-10107-10120013981390

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%2.018.00.010.0%6.034.00.015.0%6.052.00.010.3%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%10.027.03.025.0%16.039.03.027.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.058.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%10.027.03.025.0%16.039.03.027.6%

Fundamentals of Acasti Pharma Inc

About Acasti Pharma Inc

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Fundamental data was last updated by Penke on 2024-03-20 08:44:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Acasti Pharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Acasti Pharma Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Acasti Pharma Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Acasti Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM22,724.2%-22,724.2%
TTM22,724.2%YOY-11,265.1%+33,989.4%
TTM22,724.2%5Y1,712.0%+21,012.2%
5Y1,712.0%10Y-8,554.0%+10,266.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--171.8%+171.8%
TTM22,724.2%-205.8%+22,930.0%
YOY-11,265.1%-262.1%-11,003.0%
5Y1,712.0%-455.6%+2,167.6%
10Y-8,554.0%-589.0%-7,965.0%
1.1.2. Return on Assets

Shows how efficient Acasti Pharma Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Acasti Pharma Inc to the Biotechnology industry mean.
  • -3.1% Return on Assets means that Acasti Pharma Inc generated $-0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Acasti Pharma Inc:

  • The MRQ is -3.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.1%TTM-12.5%+9.4%
TTM-12.5%YOY-3.5%-9.0%
TTM-12.5%5Y-13.3%+0.7%
5Y-13.3%10Y-15.2%+2.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.1%-12.5%+9.4%
TTM-12.5%-12.2%-0.3%
YOY-3.5%-11.2%+7.7%
5Y-13.3%-13.4%+0.1%
10Y-15.2%-14.7%-0.5%
1.1.3. Return on Equity

Shows how efficient Acasti Pharma Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Acasti Pharma Inc to the Biotechnology industry mean.
  • -3.7% Return on Equity means Acasti Pharma Inc generated $-0.04 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Acasti Pharma Inc:

  • The MRQ is -3.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -14.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.7%TTM-14.6%+10.9%
TTM-14.6%YOY-4.2%-10.3%
TTM-14.6%5Y-27.0%+12.4%
5Y-27.0%10Y-23.8%-3.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.7%-15.8%+12.1%
TTM-14.6%-15.7%+1.1%
YOY-4.2%-13.9%+9.7%
5Y-27.0%-18.3%-8.7%
10Y-23.8%-19.2%-4.6%

1.2. Operating Efficiency of Acasti Pharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Acasti Pharma Inc is operating .

  • Measures how much profit Acasti Pharma Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Acasti Pharma Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Acasti Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-23,235.2%+23,235.2%
TTM-23,235.2%YOY-12,162.6%-11,072.5%
TTM-23,235.2%5Y-7,429.7%-15,805.4%
5Y-7,429.7%10Y-14,260.9%+6,831.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.1%+299.1%
TTM-23,235.2%-210.1%-23,025.1%
YOY-12,162.6%-279.7%-11,882.9%
5Y-7,429.7%-459.9%-6,969.8%
10Y-14,260.9%-596.9%-13,664.0%
1.2.2. Operating Ratio

Measures how efficient Acasti Pharma Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Acasti Pharma Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-142.563+142.563
TTM-142.563YOY158.579-301.142
TTM-142.5635Y6.721-149.283
5Y6.72110Y111.161-104.440
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.861-2.861
TTM-142.5633.193-145.756
YOY158.5793.615+154.964
5Y6.7215.560+1.161
10Y111.1617.396+103.765

1.3. Liquidity of Acasti Pharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Acasti Pharma Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 15.19 means the company has $15.19 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Acasti Pharma Inc:

  • The MRQ is 15.189. The company is very able to pay all its short-term debts. +2
  • The TTM is 14.116. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ15.189TTM14.116+1.073
TTM14.116YOY11.172+2.944
TTM14.1165Y11.232+2.884
5Y11.23210Y9.148+2.083
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.1893.986+11.203
TTM14.1164.440+9.676
YOY11.1725.552+5.620
5Y11.2326.158+5.074
10Y9.1486.492+2.656
1.3.2. Quick Ratio

Measures if Acasti Pharma Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Acasti Pharma Inc to the Biotechnology industry mean.
  • A Quick Ratio of 18.44 means the company can pay off $18.44 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Acasti Pharma Inc:

  • The MRQ is 18.442. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 14.561. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ18.442TTM14.561+3.881
TTM14.561YOY12.118+2.443
TTM14.5615Y12.386+2.175
5Y12.38610Y11.772+0.614
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ18.4423.638+14.804
TTM14.5614.168+10.393
YOY12.1185.515+6.603
5Y12.3866.012+6.374
10Y11.7726.209+5.563

1.4. Solvency of Acasti Pharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Acasti Pharma Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Acasti Pharma Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.15 means that Acasti Pharma Inc assets are financed with 15.1% credit (debt) and the remaining percentage (100% - 15.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Acasti Pharma Inc:

  • The MRQ is 0.151. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.141. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.151TTM0.141+0.010
TTM0.141YOY0.167-0.026
TTM0.1415Y0.337-0.197
5Y0.33710Y0.316+0.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1510.335-0.184
TTM0.1410.330-0.189
YOY0.1670.267-0.100
5Y0.3370.367-0.030
10Y0.3160.378-0.062
1.4.2. Debt to Equity Ratio

Measures if Acasti Pharma Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Acasti Pharma Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 17.8% means that company has $0.18 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Acasti Pharma Inc:

  • The MRQ is 0.178. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.164. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.178TTM0.164+0.014
TTM0.164YOY0.200-0.036
TTM0.1645Y0.819-0.655
5Y0.81910Y0.619+0.200
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1780.376-0.198
TTM0.1640.398-0.234
YOY0.2000.334-0.134
5Y0.8190.429+0.390
10Y0.6190.476+0.143

2. Market Valuation of Acasti Pharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Acasti Pharma Inc generates.

  • Above 15 is considered overpriced but always compare Acasti Pharma Inc to the Biotechnology industry mean.
  • A PE ratio of -4.72 means the investor is paying $-4.72 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Acasti Pharma Inc:

  • The EOD is -5.555. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.722. Based on the earnings, the company is expensive. -2
  • The TTM is -1.973. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.555MRQ-4.722-0.833
MRQ-4.722TTM-1.973-2.749
TTM-1.973YOY-0.598-1.375
TTM-1.9735Y-0.376-1.597
5Y-0.37610Y-0.523+0.147
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.555-2.643-2.912
MRQ-4.722-2.418-2.304
TTM-1.973-2.742+0.769
YOY-0.598-4.123+3.525
5Y-0.376-6.257+5.881
10Y-0.523-6.478+5.955
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Acasti Pharma Inc:

  • The EOD is -7.021. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.968. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.720. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.021MRQ-5.968-1.053
MRQ-5.968TTM-2.720-3.247
TTM-2.720YOY-0.678-2.042
TTM-2.7205Y-1.066-1.654
5Y-1.06610Y-1.372+0.306
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.021-3.244-3.777
MRQ-5.968-2.939-3.029
TTM-2.720-3.478+0.758
YOY-0.678-5.592+4.914
5Y-1.066-8.473+7.407
10Y-1.372-8.881+7.509
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Acasti Pharma Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.70 means the investor is paying $0.70 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Acasti Pharma Inc:

  • The EOD is 0.821. Based on the equity, the company is cheap. +2
  • The MRQ is 0.698. Based on the equity, the company is cheap. +2
  • The TTM is 0.355. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.821MRQ0.698+0.123
MRQ0.698TTM0.355+0.343
TTM0.355YOY0.097+0.258
TTM0.3555Y-0.763+1.119
5Y-0.76310Y0.042-0.805
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.8212.124-1.303
MRQ0.6982.041-1.343
TTM0.3552.118-1.763
YOY0.0972.915-2.818
5Y-0.7633.682-4.445
10Y0.0424.114-4.072
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Acasti Pharma Inc.

3.1. Institutions holding Acasti Pharma Inc

Institutions are holding 6.09% of the shares of Acasti Pharma Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Bank of America Corp5.26310.00024946984946980
2023-09-30UBS Group AG0.05010471247120
2023-09-30JPMorgan Chase & Co0.03570335833580
2023-09-30Morgan Stanley - Brokerage Accounts0.020188218820
2023-09-30Royal Bank of Canada0.006205845840
2023-09-30Nbc Securities Inc00220
2023-09-30TD Waterhouse Canada Inc00110
2023-12-31LLBH Private Wealth Management, LLC000-10000-100
2023-09-30TWO SIGMA SECURITIES, LLC000-2514-100
Total 5.37510.0002505237+492723+97.5%

3.2. Funds holding Acasti Pharma Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Fidelity Nasdaq Composite Index0.03250.0001305800
2024-02-29Unusual Whales Subversive Rep Trd ETF0.01240.0385116800
Total 0.04490.0386422600.0%

3.3. Insider Transactions

Insiders are holding 16.021% of the shares of Acasti Pharma Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-09-25Vimal KavuruBUY6763711.85
2023-08-31Donald OldsBUY3812.05

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Acasti Pharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.090-0.859-21%-0.281-74%0.119-1016%0.045-2527%
Book Value Per Share--4.1394.926-16%8.021-48%4.1550%2.748+51%
Current Ratio--15.18914.116+8%11.172+36%11.232+35%9.148+66%
Debt To Asset Ratio--0.1510.141+7%0.167-9%0.337-55%0.316-52%
Debt To Equity Ratio--0.1780.164+9%0.200-11%0.819-78%0.619-71%
Dividend Per Share----0%-0%-0%-0%
Eps---0.153-0.269+76%-0.338+121%-0.533+249%-0.370+142%
Free Cash Flow Per Share---0.121-0.259+114%-0.308+155%-0.346+186%-0.280+131%
Free Cash Flow To Equity Per Share---0.125-0.116-7%-0.293+134%0.110-214%0.113-211%
Gross Profit Margin--1.0131.004+1%1.021-1%1.028-1%1.0140%
Intrinsic Value_10Y_max--2.084--------
Intrinsic Value_10Y_min---10.212--------
Intrinsic Value_1Y_max---0.927--------
Intrinsic Value_1Y_min---1.153--------
Intrinsic Value_3Y_max---1.921--------
Intrinsic Value_3Y_min---3.372--------
Intrinsic Value_5Y_max---1.870--------
Intrinsic Value_5Y_min---5.474--------
Market Cap31957960.000-4%33253082.73017168680.408+94%7431165.640+347%10720339.660+210%10989013.933+203%
Net Profit Margin---227.242-100%-112.6510%17.120-100%-85.5400%
Operating Margin----232.3520%-121.6260%-74.2970%-142.6090%
Operating Ratio----142.5630%158.579-100%6.721-100%111.161-100%
Pb Ratio0.821+15%0.6980.355+96%0.097+618%-0.763+209%0.042+1557%
Pe Ratio-5.555-18%-4.722-1.973-58%-0.598-87%-0.376-92%-0.523-89%
Price Per Share3.400+15%2.8901.665+74%0.791+266%1.106+161%1.097+164%
Price To Free Cash Flow Ratio-7.021-18%-5.968-2.720-54%-0.678-89%-1.066-82%-1.372-77%
Price To Total Gains Ratio-3.121-18%-2.6532.109-226%-3.006+13%-1.656-38%-0.744-72%
Quick Ratio--18.44214.561+27%12.118+52%12.386+49%11.772+57%
Return On Assets---0.031-0.125+300%-0.035+13%-0.133+323%-0.152+386%
Return On Equity---0.037-0.146+295%-0.042+15%-0.270+631%-0.238+544%
Total Gains Per Share---1.090-0.859-21%-0.281-74%0.119-1016%0.045-2527%
Usd Book Value--47623884.00048483514.250-2%75389204.775-37%39507259.071+21%26293302.657+81%
Usd Book Value Change Per Share---1.090-0.859-21%-0.281-74%0.119-1016%0.045-2527%
Usd Book Value Per Share--4.1394.926-16%8.021-48%4.1550%2.748+51%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.153-0.269+76%-0.338+121%-0.533+249%-0.370+142%
Usd Free Cash Flow---1393079.600-2499554.425+79%-2897482.823+108%-3279931.054+135%-2509202.695+80%
Usd Free Cash Flow Per Share---0.121-0.259+114%-0.308+155%-0.346+186%-0.280+131%
Usd Free Cash Flow To Equity Per Share---0.125-0.116-7%-0.293+134%0.110-214%0.113-211%
Usd Market Cap31957960.000-4%33253082.73017168680.408+94%7431165.640+347%10720339.660+210%10989013.933+203%
Usd Price Per Share3.400+15%2.8901.665+74%0.791+266%1.106+161%1.097+164%
Usd Profit---1760493.300-7219421.500+310%-3195910.150+82%-4434573.345+152%-3438806.769+95%
Usd Revenue----5890.4000%8283.375-100%11928.060-100%15400.712-100%
Usd Total Gains Per Share---1.090-0.859-21%-0.281-74%0.119-1016%0.045-2527%
 EOD+3 -5MRQTTM+16 -15YOY+21 -115Y+19 -1410Y+21 -11

4.2. Fundamental Score

Let's check the fundamental score of Acasti Pharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.555
Price to Book Ratio (EOD)Between0-10.821
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than118.442
Current Ratio (MRQ)Greater than115.189
Debt to Asset Ratio (MRQ)Less than10.151
Debt to Equity Ratio (MRQ)Less than10.178
Return on Equity (MRQ)Greater than0.15-0.037
Return on Assets (MRQ)Greater than0.05-0.031
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Acasti Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.317
Ma 20Greater thanMa 503.401
Ma 50Greater thanMa 1002.972
Ma 100Greater thanMa 2002.672
OpenGreater thanClose3.400
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in CAD. All numbers in thousands.

Summary
Total Assets76,185
Total Liabilities11,505
Total Stockholder Equity64,680
 As reported
Total Liabilities 11,505
Total Stockholder Equity+ 64,680
Total Assets = 76,185

Assets

Total Assets76,185
Total Current Assets26,884
Long-term Assets49,301
Total Current Assets
Cash And Cash Equivalents 18,545
Short-term Investments 6,569
Net Receivables 959
Other Current Assets 811
Total Current Assets  (as reported)26,884
Total Current Assets  (calculated)26,884
+/-0
Long-term Assets
Property Plant Equipment 35
Goodwill 8,138
Intangible Assets 41,128
Long-term Assets  (as reported)49,301
Long-term Assets  (calculated)49,301
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,770
Long-term Liabilities9,735
Total Stockholder Equity64,680
Total Current Liabilities
Short-term Debt 24
Accounts payable 913
Other Current Liabilities 1,746
Total Current Liabilities  (as reported)1,770
Total Current Liabilities  (calculated)2,683
+/- 913
Long-term Liabilities
Capital Lease Obligations 24
Long-term Liabilities  (as reported)9,735
Long-term Liabilities  (calculated)24
+/- 9,711
Total Stockholder Equity
Common Stock261,038
Retained Earnings -207,953
Accumulated Other Comprehensive Income -6,038
Other Stockholders Equity 17,633
Total Stockholder Equity (as reported)64,680
Total Stockholder Equity (calculated)64,680
+/-0
Other
Capital Stock261,038
Cash and Short Term Investments 25,114
Common Stock Shares Outstanding 11,506
Current Deferred Revenue-913
Liabilities and Stockholders Equity 76,185
Net Debt -18,521
Net Invested Capital 64,680
Net Working Capital 25,114
Property Plant and Equipment Gross 35
Short Long Term Debt Total 24



Balance Sheet

Currency in CAD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-09-30
> Total Assets 
0
0
0
1,013
889
672
535
3,592
3,403
10,690
10,318
14,231
15,820
14,666
13,747
13,185
11,888
10,988
24,542
24,023
41,011
41,011
38,042
34,051
29,739
29,739
24,942
23,131
21,044
21,044
17,991
16,069
19,823
19,121
17,321
15,926
21,809
17,778
20,465
15,418
43,801
36,302
29,359
28,584
29,763
22,853
20,142
13,832
30,303
62,458
60,453
119,796
114,227
128,620
124,931
120,911
116,801
79,123
73,033
78,210
76,185
76,18578,21073,03379,123116,801120,911124,931128,620114,227119,79660,45362,45830,30313,83220,14222,85329,76328,58429,35936,30243,80115,41820,46517,77821,80915,92617,32119,12119,82316,06917,99121,04421,04423,13124,94229,73929,73934,05138,04241,01141,01124,02324,54210,98811,88813,18513,74714,66615,82014,23110,31810,6903,4033,5925356728891,013000
   > Total Current Assets 
0
0
0
996
860
643
500
3,558
3,365
3,141
2,956
7,414
8,908
8,158
7,155
6,749
5,724
5,004
4,801
5,004
23,203
23,203
20,840
18,215
15,699
15,699
12,398
11,058
8,358
8,358
6,516
4,600
6,196
7,723
6,138
4,717
10,729
7,350
10,524
5,697
35,046
27,959
21,407
20,976
22,668
16,079
13,964
13,713
30,198
62,372
60,387
54,545
48,997
45,531
41,248
37,505
33,428
29,290
23,612
28,887
26,884
26,88428,88723,61229,29033,42837,50541,24845,53148,99754,54560,38762,37230,19813,71313,96416,07922,66820,97621,40727,95935,0465,69710,5247,35010,7294,7176,1387,7236,1964,6006,5168,3588,35811,05812,39815,69915,69918,21520,84023,20323,2035,0044,8015,0045,7246,7497,1558,1588,9087,4142,9563,1413,3653,558500643860996000
       Cash And Cash Equivalents 
0
0
0
108
393
259
7
2,013
329
416
324
127
1,599
1,187
1,101
767
1,169
830
1,144
2,666
607
607
0
1,597
1,047
1,047
1,967
3,549
2,234
2,234
2,210
1,350
7,949
7,340
5,818
4,296
9,920
6,367
9,778
4,620
21,213
16,867
15,936
19,498
19,657
14,240
12,122
11,552
26,546
50,942
40,975
36,929
33,013
30,339
38,377
34,926
26,241
27,875
21,633
26,991
18,545
18,54526,99121,63327,87526,24134,92638,37730,33933,01336,92940,97550,94226,54611,55212,12214,24019,65719,49815,93616,86721,2134,6209,7786,3679,9204,2965,8187,3407,9491,3502,2102,2342,2343,5491,9671,0471,0471,59706076072,6661,1448301,1697671,1011,1871,5991273244163292,0137259393108000
       Short-term Investments 
0
0
0
0
0
0
0
981
2,564
2,064
1,548
6,082
5,575
5,143
4,094
3,853
3,505
2,913
2,618
722
20,695
20,695
19,480
15,534
13,644
13,644
9,939
6,996
5,493
5,493
3,233
2,999
0
0
0
0
0
0
0
0
12,295
8,886
3,416
20
20
5
5
0
1,372
9,789
16,747
13,861
13,312
13,322
16
14
5,015
15
15
15
6,569
6,5691515155,015141613,32213,31213,86116,7479,7891,37205520203,4168,88612,295000000002,9993,2335,4935,4936,9969,93913,64413,64415,53419,48020,69520,6957222,6182,9133,5053,8534,0945,1435,5756,0821,5482,0642,5649810000000
       Net Receivables 
0
0
0
379
468
384
493
555
456
319
649
675
1,089
1,233
1,459
1,828
817
1,009
781
951
1,034
1,034
810
507
683
683
309
306
294
294
129
110
94
155
85
196
301
588
470
907
1,382
1,188
1,406
961
1,191
546
495
625
619
530
448
813
238
548
964
859
778
802
837
837
959
9598378378027788599645482388134485306196254955461,1919611,4061,1881,38290747058830119685155941101292942943063096836835078101,0341,0349517811,0098171,8281,4591,2331,089675649319456555493384468379000
       Other Current Assets 
0
0
0
509
0
0
0
10
15
43
37
35
42
27
35
36
16
42
195
307
632
632
286
341
255
255
123
151
337
337
945
142
132
157
235
226
331
81
65
20
19
49
50
49
139
195
499
1,536
1,647
1,111
2,217
2,942
2,434
1,322
1,891
1,706
1,394
598
1,127
1,044
811
8111,0441,1275981,3941,7061,8911,3222,4342,9422,2171,1111,6471,536499195139495049192065813312262351571321429453373371511232552553412866326323071954216363527423537431510000509000
   > Long-term Assets 
0
0
0
17
28
29
35
34
39
7,548
7,361
6,817
6,912
6,508
6,593
6,436
6,164
5,984
19,742
19,019
17,809
17,809
17,202
15,836
14,040
14,040
12,544
12,072
12,687
12,687
11,476
11,468
0
0
11,183
11,209
11,080
10,428
9,941
9,721
8,755
8,343
7,952
7,608
7,096
6,774
6,178
119
105
86
66
65,251
65,230
83,089
83,683
83,406
83,373
49,833
49,421
49,323
49,301
49,30149,32349,42149,83383,37383,40683,68383,08965,23065,25166861051196,1786,7747,0967,6087,9528,3438,7559,7219,94110,42811,08011,20911,1830011,46811,47612,68712,68712,07212,54414,04014,04015,83617,20217,80917,80919,01919,7425,9846,1646,4366,5936,5086,9126,8177,3617,548393435292817000
       Property Plant Equipment 
0
0
0
17
28
29
35
34
39
36
33
29
27
24
23
21
19
17
16
14
35
35
66
62
56
56
149
235
212
212
977
1,671
2,158
2,093
2,104
2,159
2,212
2,184
2,260
2,351
2,208
2,107
2,072
2,216
2,175
2,057
2,061
119
105
86
66
43
22
315
909
632
599
567
155
57
35
3557155567599632909315224366861051192,0612,0572,1752,2162,0722,1072,2082,3512,2602,1842,2122,1592,1042,0932,1581,6719772122122351495656626635351416171921232427293336393435292817000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,964
12,964
12,964
12,964
8,138
8,138
8,138
8,138
8,1388,1388,1388,13812,96412,96412,96412,96400000000000000000000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20
20
0
27
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000270202000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
7,512
7,328
6,788
6,885
6,483
6,613
6,415
6,145
5,966
19,726
19,005
17,774
17,774
17,136
15,775
13,984
13,984
12,395
11,837
10,999
10,999
10,499
9,797
9,459
9,305
9,079
9,050
8,466
7,794
7,212
6,892
6,111
5,799
5,456
4,971
4,594
4,244
3,925
0
0
0
0
65,208
65,208
69,810
69,810
69,810
69,810
41,128
41,128
41,128
41,128
41,12841,12841,12841,12869,81069,81069,81069,81065,20865,20800003,9254,2444,5944,9715,4565,7996,1116,8927,2127,7948,4669,0509,0799,3059,4599,79710,49910,99910,99911,83712,39513,98413,98415,77517,13617,77417,77419,00519,7265,9666,1456,4156,6136,4836,8856,7887,3287,512000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
7,577
0
0
0
0
6,613
0
6,104
5,925
19,720
0
17,871
17,617
0
0
0
0
0
0
0
0
10,487
0
9,459
0
9,108
8,975
0
450
448
0
0
417
0
557
0
473
192
0
0
0
0
60,824
0
0
0
0
0
0
0
0
0
00000000060,8240000192473055704170044845008,9759,10809,459010,4870000000017,61717,871019,7205,9256,10406,61300007,577000000000
> Total Liabilities 
0
0
0
4,319
4,533
4,636
4,915
4,487
5,241
1,597
2,659
1,145
1,267
1,627
1,429
2,073
2,390
2,915
3,688
4,687
11,102
11,102
8,530
3,162
3,181
3,181
1,395
1,418
957
957
1,177
1,354
2,993
2,819
2,729
3,991
9,695
11,410
14,732
26,891
21,317
25,846
26,642
29,846
34,494
9,859
9,106
4,959
4,588
6,798
6,996
5,592
3,165
20,350
20,528
20,747
20,081
11,168
9,023
11,465
11,505
11,50511,4659,02311,16820,08120,74720,52820,3503,1655,5926,9966,7984,5884,9599,1069,85934,49429,84626,64225,84621,31726,89114,73211,4109,6953,9912,7292,8192,9931,3541,1779579571,4181,3953,1813,1813,1628,53011,10211,1024,6873,6882,9152,3902,0731,4291,6271,2671,1452,6591,5975,2414,4874,9154,6364,5334,319000
   > Total Current Liabilities 
0
0
0
4,319
4,533
4,636
4,915
4,487
967
1,414
2,659
1,145
1,267
1,627
1,429
2,073
2,390
2,915
3,688
4,687
1,052
1,052
2,216
1,718
1,297
1,297
923
1,216
842
842
1,132
1,309
1,808
1,606
1,550
2,734
3,974
5,186
7,792
10,197
10,171
13,665
13,323
11,613
10,948
7,395
5,979
3,751
2,248
1,579
2,345
4,476
2,897
3,260
3,707
3,805
3,433
3,411
1,966
1,397
1,770
1,7701,3971,9663,4113,4333,8053,7073,2602,8974,4762,3451,5792,2483,7515,9797,39510,94811,61313,32313,66510,17110,1977,7925,1863,9742,7341,5501,6061,8081,3091,1328428421,2169231,2971,2971,7182,2161,0521,0524,6873,6882,9152,3902,0731,4291,6271,2671,1452,6591,4149674,4874,9154,6364,5334,319000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
61
0
344
0
0
0
8
0
0
0
8
1,056
1,125
1,206
1,244
1
0
0
0
1,361
1,422
1,450
1,499
76
79
81
105
86
66
43
22
104
645
70
73
75
80
46
24
244680757370645104224366861058179761,4991,4501,4221,36100011,2441,2061,1251,056800080003440610000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
344
0
0
0
8
0
0
0
8
1,056
1,125
1,206
1,244
1
0
0
0
1,817
1,422
1,450
1,499
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000001,4991,4501,4221,81700011,2441,2061,1251,05680008000344000000000000000000000000
       Accounts payable 
0
0
0
0
0
803
1,090
508
974
647
977
707
552
800
832
902
318
619
1,287
2,024
287
287
1,301
1,095
197
197
816
1,191
277
277
1,039
1,299
401
195
1,492
2,679
3,974
2,648
7,792
10,197
10,171
3,044
11,901
10,163
9,449
1,713
5,900
3,670
2,143
115
2,279
4,433
2,843
1,678
3,062
3,735
3,360
1,242
607
685
913
9136856071,2423,3603,7353,0621,6782,8434,4332,2791152,1433,6705,9001,7139,44910,16311,9013,04410,17110,1977,7922,6483,9742,6791,4921954011,2991,0392772771,1918161971971,0951,3012872872,0241,2876193189028328005527079776479745081,09080300000
       Other Current Liabilities 
0
0
0
4,319
4,533
4,636
4,915
4,487
967
768
1,683
439
714
827
597
1,171
2,072
2,296
2,401
2,663
765
765
855
623
1,100
1,100
107
24
565
565
93
11
1,407
1,411
58
55
60
2,538
0
0
0
9,261
0
0
0
5,606
5,900
3,670
2,143
1,378
2,279
4,433
32
1,478
3,062
3,735
3,360
2,094
1,886
1,351
1,746
1,7461,3511,8862,0943,3603,7353,0621,478324,4332,2791,3782,1433,6705,9005,6060009,2610002,5386055581,4111,4071193565565241071,1001,1006238557657652,6632,4012,2962,0721,1715978277144391,6837689674,4874,9154,6364,5334,319000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
4,274
183
977
707
552
800
832
902
318
619
1,287
2,024
10,049
10,049
6,314
1,444
1,884
1,884
472
202
115
115
44
45
0
0
1,179
1,258
5,722
6,224
6,940
16,695
11,146
12,180
13,318
18,233
23,546
2,464
3,127
1,208
2,340
5,219
4,651
1,116
268
17,090
16,821
16,942
16,648
7,757
7,057
10,068
9,735
9,73510,0687,0577,75716,64816,94216,82117,0902681,1164,6515,2192,3401,2083,1272,46423,54618,23313,31812,18011,14616,6956,9406,2245,7221,2581,1790045441151152024721,8841,8841,4446,31410,04910,0492,0241,2876193189028328005527079771834,27400000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
949
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000009490000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
132
184
0
0
0
0
0
0
0
0
0
0
10,104
6,006
6,314
1,460
1,881
518
476
203
115
95
44
45
141
157
58
41
4,491
4,976
5,661
15,498
5,289
16,263
17,484
24,137
30,758
2,393
3,071
1,170
2,340
5,219
4,651
1,116
268
16,899
16,647
16,492
16,218
0
7,057
0
0
007,057016,21816,49216,64716,8992681,1164,6515,2192,3401,1703,0712,39330,75824,13717,48416,2635,28915,4985,6614,9764,49141581571414544951152034765181,8811,4606,3146,00610,104000000000018413200000000
> Total Stockholder Equity
0
0
0
-3,306
-3,644
-3,964
-4,379
-895
-1,838
9,092
7,658
13,086
14,553
13,039
12,319
11,112
9,498
8,072
20,854
19,337
29,910
29,910
29,511
30,889
26,558
26,558
23,546
21,713
20,087
20,087
16,814
14,715
16,830
16,302
14,592
11,935
12,114
6,368
5,732
-11,474
22,484
10,457
2,717
-1,262
-4,731
12,994
11,036
8,873
25,715
55,660
53,457
114,204
111,062
108,270
104,403
100,164
96,720
67,955
64,010
66,745
64,680
64,68066,74564,01067,95596,720100,164104,403108,270111,062114,20453,45755,66025,7158,87311,03612,994-4,731-1,2622,71710,45722,484-11,4745,7326,36812,11411,93514,59216,30216,83014,71516,81420,08720,08721,71323,54626,55826,55830,88929,51129,91029,91019,33720,8548,0729,49811,11212,31913,03914,55313,0867,6589,092-1,838-895-4,379-3,964-3,644-3,306000
   Common Stock
0
0
0
7,241
7,362
7,335
7,298
11,808
12,310
16,744
16,630
26,085
28,916
27,704
29,057
28,831
28,252
28,081
42,755
43,708
54,848
54,848
56,434
53,571
49,256
49,256
46,716
46,264
45,733
45,733
47,341
46,127
50,053
50,008
51,203
53,713
57,634
56,789
60,477
61,594
94,933
96,853
99,295
115,147
124,950
137,424
139,189
142,570
162,196
197,194
197,194
257,995
257,990
257,990
258,185
258,294
258,294
258,294
258,294
261,038
261,038
261,038261,038258,294258,294258,294258,294258,185257,990257,990257,995197,194197,194162,196142,570139,189137,424124,950115,14799,29596,85394,93361,59460,47756,78957,63453,71351,20350,00850,05346,12747,34145,73345,73346,26446,71649,25649,25653,57156,43454,84854,84843,70842,75528,08128,25228,83129,05727,70428,91626,08516,63016,74412,31011,8087,2987,3357,3627,241000
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income -6,038-6,038-6,038-6,038-6,038-6,040-6,039-6,037-6,533-6,720-5,571-6,333-6,934-7,400-7,579-7,887-7,88700-888000-5270000000-82-8200-42-4200-44-44000-42000-35000-25000-110000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,383
8,150
6,369
7,130
7,483
9,797
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000009,7977,4837,1306,3698,1504,3830000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
30
63
133
16,938
17,249
24,284
27,817
27,331
28,914
29,325
868
1,345
2,049
3,042
3,556
3,556
4,358
4,382
3,967
3,967
3,652
3,650
3,679
3,679
3,934
3,948
175
232
4,643
5,105
5,564
6,153
5,930
6,289
6,212
7,321
6,790
7,510
7,942
9,797
10,432
10,855
10,825
10,817
10,970
11,084
11,538
12,154
12,618
13,200
13,643
13,965
14,043
17,307
17,633
17,63317,30714,04313,96513,64313,20012,61812,15411,53811,08410,97010,81710,82510,85510,4329,7977,9427,5106,7907,3216,2126,2895,9306,1535,5645,1054,6432321753,9483,9343,6793,6793,6503,6523,9673,9674,3824,3583,5563,5563,0422,0491,34586829,32528,91427,33127,81724,28417,24916,9381336330000000



Balance Sheet

Currency in CAD. All numbers in thousands.




Cash Flow

Currency in CAD. All numbers in thousands.




Income Statement

Currency in CAD. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-52,155
Gross Profit-52,155-52,155
 
Operating Income (+$)
Gross Profit-52,155
Operating Expense-18,247
Operating Income15,723-70,402
 
Operating Expense (+$)
Research Development9,972
Selling General Administrative8,076
Selling And Marketing Expenses136
Operating Expense18,24718,184
 
Net Interest Income (+$)
Interest Income246
Interest Expense-67,694
Other Finance Cost-67,694
Net Interest Income246
 
Pretax Income (+$)
Operating Income15,723
Net Interest Income246
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-51,97183,417
EBIT - interestExpense = -51,971
-51,971
25,265
Interest Expense67,694
Earnings Before Interest and Taxes (EBIT)15,72315,723
Earnings Before Interest and Taxes (EBITDA)15,847
 
After tax Income (+$)
Income Before Tax-51,971
Tax Provision--9,542
Net Income From Continuing Ops-42,429-42,429
Net Income-42,429
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses18,247
Total Other Income/Expenses Net-67,694-246
 

Technical Analysis of Acasti Pharma Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Acasti Pharma Inc. The general trend of Acasti Pharma Inc is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Acasti Pharma Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Acasti Pharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 3.4506 < 3.5 < 3.59.

The bearish price targets are: 3.325 > 3.2629 > 3.18.

Tweet this
Acasti Pharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Acasti Pharma Inc. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Acasti Pharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Acasti Pharma Inc. The current macd is 0.10029404.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Acasti Pharma Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Acasti Pharma Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Acasti Pharma Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Acasti Pharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartAcasti Pharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Acasti Pharma Inc. The current adx is 36.19.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Acasti Pharma Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Acasti Pharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Acasti Pharma Inc. The current sar is 3.53699853.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Acasti Pharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Acasti Pharma Inc. The current rsi is 62.32. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 3/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
Acasti Pharma Inc Daily Relative Strength Index (RSI) ChartAcasti Pharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Acasti Pharma Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Acasti Pharma Inc price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Acasti Pharma Inc Daily Stochastic Oscillator ChartAcasti Pharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Acasti Pharma Inc. The current cci is 32.09.

Acasti Pharma Inc Daily Commodity Channel Index (CCI) ChartAcasti Pharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Acasti Pharma Inc. The current cmo is 19.65.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Acasti Pharma Inc Daily Chande Momentum Oscillator (CMO) ChartAcasti Pharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Acasti Pharma Inc. The current willr is -26.95791156.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Acasti Pharma Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Acasti Pharma Inc Daily Williams %R ChartAcasti Pharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Acasti Pharma Inc.

Acasti Pharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Acasti Pharma Inc. The current atr is 0.11381887.

Acasti Pharma Inc Daily Average True Range (ATR) ChartAcasti Pharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Acasti Pharma Inc. The current obv is 2,210,300.

Acasti Pharma Inc Daily On-Balance Volume (OBV) ChartAcasti Pharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Acasti Pharma Inc. The current mfi is 26.83.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Acasti Pharma Inc Daily Money Flow Index (MFI) ChartAcasti Pharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Acasti Pharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-11-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Acasti Pharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Acasti Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.317
Ma 20Greater thanMa 503.401
Ma 50Greater thanMa 1002.972
Ma 100Greater thanMa 2002.672
OpenGreater thanClose3.400
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Acasti Pharma Inc with someone you think should read this too:
  • Are you bullish or bearish on Acasti Pharma Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Acasti Pharma Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Acasti Pharma Inc

I send you an email if I find something interesting about Acasti Pharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Acasti Pharma Inc.

Receive notifications about Acasti Pharma Inc in your mailbox!